What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (NASDAQ:DFTX) plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company’s third-quarter earnings call.

The company also reported early findings from a five-participant autism study of its DT402 candidate and said its approximately $1.05 billion in cash, equivalents and investments at Sept. 30 should fund planned operations into 2030.

Chief Executive Officer Rob Barrow said Definium’s discussions with the Food and Drug Administration have been constructive. Asked whether a pre-NDA meeting had taken place, he did not confirm its status, saying the company is typically able to share meeting details after receiving official minutes.

DT120 Studies and Regulatory Plans

Chief Medical Officer Dan Karlin said the Phase 3 Voyage and Panorama studies each met their primary and key secondary efficacy endpoints in patients with moderate to severe generalized anxiety disorder, or GAD.

In Voyage, which enrolled 214 participants, a single 100-microgram dose produced a 5.4-point improvement over placebo on the Hamilton Anxiety Rating Scale at week 12. In Panorama, which enrolled 245 participants, the same dose produced a 5.1-point placebo-adjusted improvement at week 12. Karlin said both results had a p-value below 0.0001.

The company previously reported that Emerge, its Phase 3 study in major depressive disorder, or MDD, met its primary and key secondary endpoints. Karlin said the FDA granted DT120 ODT breakthrough therapy designation for MDD, in addition to its earlier designation for GAD.

Across the completed double-blind portions of the three studies, DT120 was generally well tolerated, with no drug-related serious adverse events or suicidality signal, Karlin said. Participants completed an end-of-session checklist in an average of about six hours across the studies.

A second Phase 3 MDD study, Ascend, continues to enroll patients, with top-line results expected in 2027. Barrow declined to detail how Ascend’s results might fit into the company’s filing strategy if they become available during an FDA review.

Definium also plans to start Haven, a Phase 3 study in post-traumatic stress disorder, in 2027. The company expects to enroll approximately 200 participants and measure the primary endpoint at week eight. Karlin said the trial will have a 12-week double-blind period and is expected to include both Veterans Affairs and non-VA sites.

Early Autism Study Stops After Five Participants

Definium ended enrollment in its open-label Phase 2a study of DT402 in adults with autism spectrum disorder after five participants. Karlin said the study was designed to look for early efficacy signals after a single dose, and the company decided it had seen a sufficiently consistent signal to stop enrolling.

Measures that improved during treatment included rigidity and fixation, social engagement, empathy and closeness to others, and anxiety and irritability, Karlin said. The most common adverse events were euphoria, fatigue and enhanced relaxation.

Karlin cautioned that the findings came from a small, early-stage study. Definium plans to initiate a study of multiday dosing in 2027.

Launch Planning and Pricing

Chief Commercial Officer Matt Wiley said Definium is developing distribution, patient services and field deployment plans to support a supervised treatment model if DT120 is approved. The company is also assessing provider capacity and infrastructure needs and plans to hold its first Commercial Day in the first half of 2027.

Asked whether a competing depression drug filing had changed Definium’s commercialization or pricing strategy, Barrow said it had not fundamentally done so. Wiley said payers had advised the company of a pricing corridor between $30,000 and $75,000 that they currently pay for SPRAVATO. He said future payer discussions would help narrow that range; Definium did not announce a price for DT120.

Third-Quarter Financial Results

Chief Financial Officer Brandi Roberts said research and development expenses rose to $46.1 million from $31 million a year earlier, primarily reflecting higher personnel costs and DT120 development spending. General and administrative expenses increased to $26.1 million from $14.7 million as the company invested in commercial preparation and other capabilities.

Definium reported a third-quarter net loss of $51 million, compared with a $67.3 million loss a year earlier. Roberts attributed the smaller loss primarily to a gain from changes in the fair value of 2022 financing warrants and higher interest income, partly offset by increased operating expenses.

About Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.